MDS Latest News
NICE states that azacitidine is not recommended as a treatment option for people with intermediate-2 or high risk myelodysplastic syndromes (MDS)
Read full story
On 4th March 2010, NICE published their final decision not to recommend the use of azacitidine (Vidaza) to treat patients with MDS in the NHS, despite its proven ability to extend patient survival and significantly improve quality of life…
Read full story
Prime minister’s office responds to the AML (Acute Myeloid Leukaemia) petition for azacitidine
Read full story
NICE to lose powers to decide on new drugs.
Read full story
“Scientists at King’s have developed a vaccine treatment for Leukaemia that can be used to stop the disease returning after chemotherapy or bone marrow transplant. The vaccine is due to be tested on patients for the first time. Eventually it is hoped the drug, which activates the body's own immune system against the leukaemia, could be used to treat other types of cancers. ” KCL website.
Read full story
This CML (Chronic Myeloid Leukaemia) patient is facing similar issues as our MDS patients with azacitidine, as NICE’s preliminary decision is NOT TO recommend 2 drugs that can treat this condition.
Read full story
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.
Read full story